Ligand Pharmaceuticals and Lilly have entered into license and supply agreements for Ligand’s Captisol platform in undisclosed therapeutic areas. Lilly will be permitted to nominate an unlimited number of drug candidates from its internal pipeline for Captisol formulation. Ligand will provide clinical supplies of Captisol, and may ultimately supply commercial quantities of Captisol to Lilly if a product should be successfully commercialized. Ligand will receive a $1 million upfront payment...